Foyston, Gordon, & Payne’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.47M | Sell |
9,044
-1,287
| -12% | -$193K | 0.31% | 53 |
|
|
2026
Q1 | $1.58M | Buy |
10,331
+135
| +1% | +$20.7K | 0.36% | 50 |
|
|
2025
Q4 | $1.41M | Sell |
10,196
-384
| -4% | -$50.3K | 0.31% | 46 |
|
|
2025
Q3 | $1.36M | Sell |
10,580
-152
| -1% | -$18.5K | 0.3% | 46 |
|
|
2025
Q2 | $1.3M | Sell |
10,732
-140
| -1% | -$15.8K | 0.3% | 44 |
|
|
2025
Q1 | $1.21M | Sell |
10,872
-112
| -1% | -$11.9K | 0.3% | 44 |
|
|
2024
Q4 | $1.07M | Buy |
10,984
+133
| +1% | +$14.2K | 0.28% | 44 |
|
|
2024
Q3 | $1.25M | Sell |
10,851
-13,005
| -55% | -$1.48M | 0.31% | 46 |
|
|
2024
Q2 | $2.54M | Sell |
23,856
-1,054
| -4% | -$106K | 0.63% | 41 |
|
|
2024
Q1 | $2.41M | Sell |
24,910
-546
| -2% | -$56K | 0.58% | 42 |
|
|
2023
Q4 | $2.57M | Buy |
25,456
+15,166
| +147% | +$1.46M | 0.65% | 45 |
|
|
2023
Q3 | $1.05M | Sell |
10,290
-102,752
| -91% | -$10.4M | 0.29% | 51 |
|
|
2023
Q2 | $11.4M | Buy |
113,042
+83,712
| +285% | +$8.37M | 2.98% | 10 |
|
|
2023
Q1 | $2.7M | Sell |
29,330
-673
| -2% | -$58.8K | 0.73% | 42 |
|
|
2022
Q4 | $2.72M | Sell |
30,003
-715
| -2% | -$60.2K | 0.75% | 45 |
|
|
2022
Q3 | $2.33M | Buy |
30,718
+19,546
| +175% | +$1.62M | 0.64% | 47 |
|
|
2022
Q2 | $2.69M | Sell |
11,172
-20,508
| -65% | -$1.8M | 0.78% | 42 |
|
|
2022
Q1 | $2.78M | Buy |
31,680
+35
| +0.1% | +$3.03K | 0.68% | 44 |
|
|
2021
Q4 | $2.77M | Sell |
31,645
-11,644
| -27% | -$967K | 0.65% | 43 |
|
|
2021
Q3 | $3.54M | Sell |
43,289
-230
| -0.5% | -$20.7K | 0.88% | 38 |
|
|
2021
Q2 | $3.97M | Sell |
43,519
-12,854
| -23% | -$1.14M | 0.94% | 36 |
|
|
2021
Q1 | $4.82M | Sell |
56,373
-877
| -2% | -$78.7K | 1.14% | 32 |
|
|
2020
Q4 | $5.41M | Sell |
57,250
-3,039
| -5% | -$266K | 1.31% | 28 |
|
|
2020
Q3 | $5.24M | Buy |
60,289
+1,534
| +3% | +$133K | 1.35% | 29 |
|
|
2020
Q2 | $5.13M | Sell |
58,755
-11,887
| -17% | -$1.03M | 1.26% | 27 |
|
|
2020
Q1 | $5.82M | Sell |
70,642
-1,771
| -2% | -$158K | 1.51% | 21 |
|
|
2019
Q4 | $6.86M | Buy |
72,413
+1,979
| +3% | +$178K | 1.29% | 26 |
|
|
2019
Q3 | $6.12M | Sell |
70,434
-10,133
| -13% | -$910K | 1.22% | 25 |
|
|
2019
Q2 | $7.36M | Sell |
80,567
-9,320
| -10% | -$789K | 1.37% | 23 |
|
|
2019
Q1 | $7.74M | Sell |
89,887
-35
| -0% | -$2.81K | 1.48% | 21 |
|
|
2018
Q4 | $6.91M | Sell |
89,922
-7,863
| -8% | -$612K | 1.39% | 22 |
|
|
2018
Q3 | $7.55M | Buy |
97,785
+720
| +0.7% | +$53.2K | 1.29% | 24 |
|
|
2018
Q2 | $6.57M | Buy |
97,065
+3,147
| +3% | +$217K | 1.21% | 25 |
|
|
2018
Q1 | $6.8M | Sell |
93,918
-747
| -0.8% | -$56.9K | 1.31% | 21 |
|
|
2017
Q4 | $7.12M | Sell |
94,665
-92,514
| -49% | -$6.98M | 1.35% | 22 |
|
|
2017
Q3 | $14.4M | Buy |
187,179
+90,054
| +93% | +$6.8M | 2.5% | 14 |
|
|
2017
Q2 | $7.26M | Sell |
97,125
-1,784
| -2% | -$126K | 1.57% | 19 |
|
|
2017
Q1 | $6.58M | Sell |
98,909
-3,088
| -3% | -$206K | 1.42% | 26 |
|
|
2016
Q4 | $6.66M | Buy |
101,997
+92,957
| +1,028% | +$6.03M | 1.58% | 25 |
|
|
2016
Q3 | $640K | Hold |
9,040
| – | – | 0.12% | 68 |
|
|
2016
Q2 | $668K | Hold |
9,040
| – | – | 0.12% | 65 |
|
|
2016
Q1 | $587K | Sell |
9,040
-75
| -0.8% | -$5.1K | 0.11% | 64 |
|
|
2015
Q4 | $703K | Hold |
9,115
| – | – | 0.13% | 62 |
|
|
2015
Q3 | $751K | Buy |
9,115
+75
| +0.8% | +$6.67K | 0.14% | 56 |
|
|
2015
Q2 | $797K | Hold |
9,040
| – | – | 0.12% | 59 |
|
|
2015
Q1 | $799K | Hold |
9,040
| – | – | 0.12% | 58 |
|
|
2014
Q4 | $751K | Hold |
9,040
| – | – | 0.11% | 66 |
|
|
2014
Q3 | $762K | Sell |
9,040
-289
| -3% | -$23.4K | 0.11% | 67 |
|
|
2014
Q2 | $757K | Hold |
9,329
| – | – | 0.1% | 67 |
|
|
2014
Q1 | $711K | Sell |
9,329
-290
| -3% | -$21.1K | 0.09% | 74 |
|
|
2013
Q4 | $693K | Hold |
9,619
| – | – | 0.09% | 78 |
|
|
2013
Q3 | $661K | Buy |
+9,619
| New | +$636K | 0.09% | 74 |
|
Other funds holding NVS
Foyston, Gordon, & Payne's NVS Position: Q2 2026 in Review
Foyston, Gordon, & Payne reduced its Novartis (NVS) stake by 12% in Q2 2026, selling an estimated $193K and leaving 9,044 shares worth $1.47M. The position accounts for 0.31% of the portfolio, ranked #53.
Foyston, Gordon, & Payne first reported a position in NVS in Q3 2013 and has held it in 52 quarters since. The position peaked at $14.4M in Q3 2017. 1,613 funds tracked by Wall St. Rank hold NVS as of Q2 2026.
- Foyston, Gordon, & Payne held 9,044 shares of Novartis worth $1.47M as of Q2 2026.
- Foyston, Gordon, & Payne sold 1,287 Novartis shares in Q2 2026, an estimated $193K.
- Novartis made up 0.31% of Foyston, Gordon, & Payne's portfolio in Q2 2026, its #53 holding.
- Foyston, Gordon, & Payne first reported a position in Novartis in Q3 2013 and has held it in 52 quarters since.
- Foyston, Gordon, & Payne's Novartis position peaked at $14.4M in Q3 2017.
- 1,613 funds tracked by Wall St. Rank held Novartis as of Q2 2026.
Based on Foyston, Gordon, & Payne's 13F filing for Q2 2026, filed 12 Aug 2026.